Evidence map›Paper›PMID 41647731›Full record

ArticleESMO gastrointestinal oncology2023

Association of PD-L1 and PD-L2 expression and tumor-infiltrating lymphocytes in

M Imai, Y Nakamura, T Denda, Y Komatsu, S Yuki, T Nishina, Y Hamamoto, H Hara, T Esaki, H Kawakami and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO gastrointestinal oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

M ImaiTranslational Research Support Office, National Cancer Center Hospital East, Kashiwa.
Y NakamuraTranslational Research Support Office, National Cancer Center Hospital East, Kashiwa.
T DendaDivision of Gastroenterology, Chiba Cancer Center, Chiba.
Y KomatsuDepartment of Cancer Center.
S YukiDepartment of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo.
T NishinaDepartment of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama.
Y HamamotoDivision of Gastroenterology and Hepatology of Internal Medicine, Keio University School of Medicine, Tokyo.
H HaraDepartment of Gastroenterology, Saitama Cancer Center, Ina.
T EsakiDepartment of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka.
H KawakamiDepartment of Medical Oncology, Kindai University Faculty of Medicine, Osaka.
K KatoDepartment of Head and Neck, Esophageal Medical Oncology, Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo.
T SatohCenter for Cancer Genomics and Precision Medicine Osaka University Hospital, Suita.
N OkanoDepartment of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo.
Y SunakawaDepartment of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki.
H TaniguchiDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya.
K YamaguchiGastroenterological Chemotherapy Department, The Cancer Institute Hospital of JFCR, Tokyo.
T YamadaDepartment of Gastroenterology, University of Tsukuba Hospital, Tsukuba.
I MikiTranslational Research Support Office, National Cancer Center Hospital East, Kashiwa.
M WakabayashiDepartment of Data Science.
T KuwataDepartment of Genetic Medicine and Services, National Cancer Center Hospital East, Kashiwa.
K ShitaraDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa.
T YoshinoDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The programmed cell death protein 1 (PD-1)/programmed cell death-ligand 1 (PD-L1)/programmed cell death-ligand 2 (PD-L2) axis is responsible for cancer immune escape, which facilitates disease progression. However, the role of PD-L1 and PD-L2 and tumor-infiltrating lymphocytes (TILs) in metastatic colorectal cancer (mCRC) has not been studied. Materials and methods: We conducted a Results: Two hundred patients with mCRC (median age 65 years and 116 males) were included in the study. Genomic testing identified Conclusions: Our study showed a distinct pattern of PD-L1 expression on TC of patients with

Indexed as

BRAF V600Emetastatic colorectal canceroverall survivalPD-L1PD-L2TIL

Identifiers

PMID41647731
PMCPMC12836720

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.